Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Tatva Chintan Pharma Chem's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was -6.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Tatva Chintan Pharma Chem's 3-Year ROIIC % or its related term are showing as below:
NSE:TATVA's 3-Year ROIIC % is ranked worse than 61.74% of 1529
companies
in the Chemicals industry
Industry Median: 0.03
vs NSE:TATVA: -6.00
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Tatva Chintan Pharma Chem 3-Year ROIIC % Related Terms
Tatva Chintan Pharma Chem 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:TATVA vs LIN, SHW, ECL: 3-Year ROIIC % Comparison
For the Specialty Chemicals subindustry, Tatva Chintan Pharma Chem's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tatva Chintan Pharma Chem 3-Year ROIIC % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Tatva Chintan Pharma Chem's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Tatva Chintan Pharma Chem's 3-Year ROIIC % falls into.
Tatva Chintan Pharma Chem's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 415.406247 (Mar. 2026) - 587.35 (Mar. 2023) )
/
( 9359.85 (Mar. 2026) - 6496.35 (Mar. 2023) )
=
-171.943753
/
2863.5
=
-6.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Tatva Chintan Pharma Chem (NSE:TATVA) has a 3-Year ROIIC % of -6.00 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tatva Chintan Pharma Chem and its competitors. According to the industry distribution chart, Tatva Chintan Pharma Chem ranks #944 out of 1529 companies in the Chemicals industry, placing it in the top 61.7%.
Is Tatva Chintan Pharma Chem's 3-Year ROIIC % too high?
Tatva Chintan Pharma Chem's current 3-Year ROIIC % is -6.00. Based on the distribution chart, Tatva Chintan Pharma Chem ranks #944 out of 1529 companies in the Chemicals industry, which is below the industry midpoint. Overall, Tatva Chintan Pharma Chem has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tatva Chintan Pharma Chem's 3-Year ROIIC % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Tatva Chintan Pharma Chem ranks #944 out of 1529 companies for 3-Year ROIIC %. This places Tatva Chintan Pharma Chem in the lower half of its industry. The industry median 3-Year ROIIC % is 0.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Chemicals company?
The median 3-Year ROIIC % among Chemicals companies is 0.03, based on 1,529 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tatva Chintan Pharma Chem and its competitors. For the Chemicals industry, the median 3-Year ROIIC % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tatva Chintan Pharma Chem's current 3-Year ROIIC % is -6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tatva Chintan Pharma Chem stock overvalued right now?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem (NSE:TATVA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,516.57, compared to a current price of ₹1,717.30 — trading 13.2% above its estimated fair value. The current 3-Year ROIIC % is -6.00. Tatva Chintan Pharma Chem's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Tatva Chintan Pharma Chem (NSE:TATVA), the current 3-Year ROIIC % is -6.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tatva Chintan Pharma Chem (NSE:TATVA) Overvalued in 2026?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem stock appears to be overvalued.
The current stock price of ₹1,717.30 is trading 13.2% above its estimated GF Value™ of ₹1,516.57.
GuruFocus considers Tatva Chintan Pharma Chem to be Modestly Overvalued.
Key valuation signals for NSE:TATVA:
3-Year ROIIC %: -6.00
GF Value™: ₹1,516.57 vs. price of ₹1,717.30 (13.2% above fair value)
No single metric tells the full story. See the NSE:TATVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacturing and selling of specialty chemicals, Pharma and Agro intermediates, Quaternary Compounds, and Quats. The company's product portfolio includes structure-directing agents, phase transfer catalysts, electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates and other specialty chemicals. The company sells its products in domestic as well as overseas markets, with the majority of revenue coming from overseas markets.
83GF Score
Get the complete analysis for NSE:TATVA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TATVA has been successfully added to your 
